Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Agomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD

Oct 13, 2026 · 04:06 PM ET· updated 1h ago

-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) ---- Global, randomized, placebo-controlled, dose-ranging

Share
Why It Matters

Agomab started testing a new medicine for a serious gut disease. This is an early sign the company is moving forward with its plan.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
AGMB8.83
-0.26 (-2.86%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.